Atopic Dermatitis

In this interview, Dr. Yu explains several important pieces of information regarding atopic dermatitis that he believes clinicians should be aware of.

Dr. Eichenfield spoke in this interview segment on the tips shared in his presentation at the Fall Clinical Dermatology conference in Las Vegas.

This interview segment explored the major takeaways from Dr. Chovatiya’s presentation on Type 2 Inflammation in eczema, prurigo nodularis, and chronic spontaneous urticaria.

In this interview segment, Dr. Chovatiya discussed the challenges of diagnosing Type 2 inflammation in several different dermatologic diseases.

In this talk presented at the Fall Clinical Dermatology conference, Dr. James Del Rosso and Dr. Alexandra Golant debate the benefits of JAK inhibitors and monoclonal antibodies.

Linda Stein Gold, MD, explains how the safety considerations of nonsteroidal topicals must be weighed against their significant value in the treatment arsenal.

Linda Stein Gold, MD, discusses the notable transition in topical therapies for both psoriasis and atopic dermatitis, with the introduction of effective FDA-approved nonsteroidal treatments.

In this interview on the conference floor at Fall Clinical Dermatology, Dr. Lio discussed the important topic of treating patients with eczema that have skin of color.

This new data was presented at EADV in Berlin, with the findings of 3 studies expanding the range of effectiveness of this treatment to 140-weeks for patients with eczema.

In this interview, Dr. Simpson discussed the latest findings presented at EADV in Berlin on the use of tapinarof cream, 1% for adults and children as young as 2 years with eczema.

The new results from 3 different phase 3 studies presented at EADV on nemolizumab for those with prurigo nodularis and eczema show promise for the treatment.

This news was announced following new findings by the FDA due to a recent inspection, though no concerns were listed regarding clinical data, labeling, or safety.

This new data resulted from the first study that found EIS could detect skin barrier dysfunction among children found to have developed atopic dermatitis early on in life.

The new educational initiative was launched to provide useful insights from dermatologists as well as personal accounts by patients with seborrheic dermatitis with many different backgrounds.

These new results from the pivotal INTEGUMENT-PED trial met both of the investigators' primary and secondary endpoints.

The sNDA was announced for roflumilast cream 0.15% to the FDA, and the formulation is said to not to be disruptive to the skin barrier or contain common irritants to patients’ skin.

This new data had both a consistent long-term safety and tolerability profile with the previous short-term results for the skin disease, and there were no new safety signals recorded.

A population-based cohort study highlighted an association between AD and IBD with risk varying by age, AD severity, and subtype of IBD.

These new results for tralokinumab could provide safer treatment options for older atopic dermatitis patients versus conventional therapies with greater risk of adverse events and drug-drug interactions.

In this latest research, the investigators noted that upadacitinib therapy may also be utilized as a treatment option for atopic dermatitis patients who experience a flare.

This new data indicates opportunities which may have been missed for initiation of fracture prevention for elderly individuals treated with oral corticosteroids.

New late-breaking trial data from the ADhere, Adjoin, ADvocate1, and ADvocate2 trials showed solid results for lebrikizumab in treating moderate-to-severe atopic dermatitis.

In her presentation ‘Treatment of Eczema in Pediatric Patients Under 12 Years,’ Dr. Garza-Mayers spoke on considerations for atopic dermatitis management.

Zirwas touts topical ruxolitinib's rapid, effective treatment of atopic dermatitis, and reviews the safety outcomes associated with JAK inhibitors.

On the basis of discovery into what drives adult-onset eczema, the novel drug may provide a unique benefit for impacted patients.

A post hoc analysis shows the investigative drug significantly improved atopic dermatitis symptoms versus placebo as soon as the first week into a phase 2 trial.

The first trial observing the topical drug in children held promise for an extended indication.

The investigator explains why he believes the PDE4 inhibitor is "as close to a perfect drug as you can hope for in seborrheic dermatitis."

Andrew Blauvelt, MD, discusses switching therapies for atopic dermatitis (AD) treatment.

Andrew Blauvelt, MD, discusses upadacitinib for the treatment of atopic dermatitis (AD).